2h
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
From molecular chaperones to mitochondrial failure, discover how heat reshapes the human transcriptome and drives the biological cascade that links rising temperatures to organ injury and public ...
A research team led by UAB researcher David Reverter has discovered the molecular mechanism that describes in detail the ...
Researchers uncover a redox-regulated mechanism that determines whether bone fractures heal or progress to nonunion ...
Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read ...
Primary immunodeficiencies are genetic disorders that impact on the immune system due to defective function of a variety of genes. Among those molecules are ...
Upregulated expression of transcription factors promoting cone identity in late-stage retinal progenitors drives development ...
Fluoxetine during auditory development drove 91 brainstem gene changes, reduced neural circuit stability, and left lasting ...
In 2025, UNC walked a tight line between protecting free speech and asserting administrative authority. Whether in classrooms, on campus walls or in student activism, debates over what should be ...
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
Driven by an innovative vector platform and efficient product design and development engine, 4D Molecular Therapeutics, or 4DMT, is developing genetic medicines with customized vectors that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results